XENIKOS
Xenikos aims to develop a new medicine, based on the action of antibodies that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos strives to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.
XENIKOS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2009-01-01
Address:
Nijmegen, Gelderland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.xenikos.com
Total Employee:
1+
Status:
Active
Contact:
+31 24 300 01 00
Email Addresses:
[email protected]
Total Funding:
84.25 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible WordPress Mobile Non Scaleable Content Sitelinks Search Box Euro Yoast WordPress SEO Plugin Google Maps ReCAPTCHA Yoast SEO Premium
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Cognition Therapeutics
Cognition Therapeutics develops new therapeutics to treat patients suffering from Alzheimer’s disease and other neurodegenerative disorders.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
Sanquin Blood Supply Foundation
Sanquin Blood Supply Foundation investment in Convertible Note - Xenikos
Medicxi
Medicxi investment in Convertible Note - Xenikos
OostNL
OostNL investment in Convertible Note - Xenikos
RA Capital Management
RA Capital Management investment in Convertible Note - Xenikos
Veloxis
Veloxis investment in Convertible Note - Xenikos
Medicxi
Medicxi investment in Series B - Xenikos
RA Capital Management
RA Capital Management investment in Series B - Xenikos
Agentschap NL
Agentschap NL investment in Debt Financing - Xenikos
Innovation & Investment Fund Gelderland
Innovation & Investment Fund Gelderland investment in Series A - Xenikos
Sanquin Blood Supply Foundation
Sanquin Blood Supply Foundation investment in Series A - Xenikos
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-22 | Xenikos Appoints Hassan Aly, MD, PhD as Chief Medical Officer |
| 2019-12-03 | Xenikos appoints Chief Financial Officer and Chief Business Officer |
Official Site Inspections
http://www.xenikos.com
- Host name: host37-5.registrar-servers.com
- IP address: 185.61.152.55
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Xenikos"
Xenikos - Crunchbase Company Profile & Funding
Xenikos aims to develop a new medicine, based on the action of antibodies that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune …See details»
OUR TEAM – Xenikos – Resetting the immune system
His work mostly focused on genome organization of synthetic cells. Joep joined the CMC team at Xenikos as Scientist Bioprocessing in January 2022, he is involved in upstream process …See details»
Xenikos – Resetting the immune system – Xenikos is developing a ...
In June 2022, Xenikos commenced a global Phase 3 clinical study evaluating T-Guard® in patients with grade III/IV steroid-refractory acute graft-versus-host disease (aGVHD) following …See details»
Xenikos' Leadership Team - Team members and org chart - The Org
About. The leadership team at Xenikos has a wealth of experience in the corporate finance, pharmaceutical, and medical industries. Many on the team have worked as consultants or in …See details»
Xenikos - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Xenikos . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 6. Number of Board …See details»
Xenikos Company Profile 2024: Valuation, Funding & Investors
Xenikos General Information Description. Developer of anti-T-cell antibodies designed to provide immunotherapy medicines to help restore patients' health. The company uses a therapeutic …See details»
Xenikos - The Org
Xenikos is developing a combination of two toxin-loaded anti-T-cell antibodies. Industries. Biotechnology, Life Sciences +1See details»
Xenikos' Board of Directors Team - Team members and org chart
The current board of directors at Xenikos has a wide range of experience in both the business and medical fields. Many of the members have worked with RA Capital Management in the past, in …See details»
Xenikos B.V.: Contact Details and Business Profile
Xenikos is a clinical-stage biotechnology company focused on developing a novel therapy that aims to quickly and efficiently reset the immune system of patients suffering from serious …See details»
Xenikos | VentureRadar
Similar Companies: Biond Biologics Israel Privately Held Biond Biologics is a discovery and development company in the field of cancer immunotherapy and autoimmune disorders.. …See details»
Xenikos - Overview, News & Similar companies | ZoomInfo.com
Xenikos. Business Services · Netherlands · <25 Employees. Xenikos, a private, clinical-stage biopharmaceutical company, is focused on developing innovative immunotherapies, based on …See details»
Xenikos BV - Drug pipelines, Patents, Clinical trials - Synapse
Xenikos , a 13-year-old Dutch biotech, is going through a liquidation process after disappointing results in its Phase III trial in graft-versus-host disease. ... The statistics for drugs in the …See details»
Xenikos - Company Profile - Tracxn
Nov 22, 2024 Xenikos ranks 30th among 192 active competitors. 62 of its competitors are funded while 59 have exited. Overall, Xenikos and its competitors have raised over $7.7B in …See details»
Xenikos - Updates, News, Events, Signals & Triggers - Crunchbase
Xenikos is developing a combination of two toxin-loaded anti-T-cell antibodies.See details»
Xenikos Company Profile - Office Locations, Competitors ... - Craft
Xenikos has 5 employees at their 1 location and $36.96 m in total funding,. See insights on Xenikos including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis ...
Sep 8, 2021 Xenikos will use the proceeds of the financing to initiate a registrational Phase 3 clinical trial in the US and EU, which is designed to evaluate the efficacy and safety of their …See details»
Xenikos - Crunchbase
Companies like Xenikos include Excision BioTherapeutics, Scholar Rock, and Affimed. Excision BioTherapeutics Philadelphia , Pennsylvania , United States 20 Contacts 11-50 employeesSee details»
Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study ...
Jun 27, 2022 Xenikos expects to report results from the safety run-in phase during the first half of 2023. The trial will also include an interim analysis for futility after 46 patients become …See details»
NEWS – Xenikos – Resetting the immune system
Sep 8, 2021 Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease. Do you like it? Read …See details»
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis ...
Sep 8, 2021 NIJMEGEN, the Netherlands – September 8, 2021 - Xenikos B.V., a clinical-stage biopharmaceutical company currently developing a novel therapy for treating immune related …See details»